US OptionsDetailed Quotes
HUMA241220C12500
- 0.07
- -0.02-22.22%
15min DelayClose Nov 22 16:00 ET
0.07High0.07Low
0.07Open0.09Pre Close2 Volume4.38K Open Interest12.50Strike Price14.00Turnover215.96%IV179.96%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type0.0775Delta0.0544Gamma59.87Leverage Ratio-0.0069Theta0.0002Rho4.64Eff Leverage0.0018Vega
Humacyte Stock Discussion
Benzinga· 3 mins ago
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...
what happened? the earnings suck but now the stock is rising
Do you think that is a credibility issue maybe they raise this company some money along the way and they need to be bullish to get potential business from them in the future.
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
Humacyte (HUMA) presented positive Phase 3 clinical trial results for their ATEV (acellular tissue engineered vessel) in arteriovenous access for hemodialysis patients. The trial demonstrated superior performance compared to standard autogenous fistula, with 81.3% functional patency at 6 months versus 66.4%, and 68.3% seco...
No comment yet